Cardiovascular and non‐renal complications of chronic kidney disease: Managing risk

Documenti analoghi

• Slowing the progression of diabetic and non‐diabetic kidney disease: A summary of the current evidence base for sodium‐glucose co‐transporter‐2 inhibitors
  di: Viktor Rotbain Curovic, et al.
  Pubblicazione: (2024)
• Effect of spironolactone wash‐out on albuminuria after long‐term treatment in individuals with type 2 diabetes and high risk of kidney disease—An observational follow‐up of the PRIORITY study
  di: Victor Wasehuus, et al.
  Pubblicazione: (2024)
• Effects of combined treatment with zibotentan and dapagliflozin compared to dapagliflozin alone in patients with diabetic and non‐diabetic chronic kidney disease
  di: Victor Wasehuus, et al.
  Pubblicazione: (2025)
• The effect of the endothelin receptor antagonist atrasentan on insulin resistance in phenotypic clusters of patients with type 2 diabetes and chronic kidney disease
  di: Johannes David Smeijer, et al.
  Pubblicazione: (2024)
• Cumulative risk of diabetic foot complications in risk groups of type 1 and type 2 diabetes: Real‐world evidence from a 22‐year follow‐up study
  di: Abhilasha Akerkar, et al.
  Pubblicazione: (2025)